

7 October 2025

Crystal Amber Fund Limited
("Crystal Amber Fund", the "Company" or the "Fund")

Investor Presentation by Morpich Medical Inc

The Board of Crystal Amber is pleased to announce that Morpich Medical Inc. ("MMI"), the medical device company in which the Fund owns 96.7% of the issued share capital, will be conducting a live investor presentation via the Investor Meet Company platform, followed immediately by a Q&A session.

This online event will take place at **10:30am on Thursday 16 October 2025**.

The presentation will be hosted by Mike Gutteridge, MMI's CEO and President, with opening remarks from Chris Waldron, Crystal Amber's Chairman.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 15 October 2025, 09:00 BST, or at any time during the live presentation.

To register, please visit: <https://www.investormeetcompany.com/crystal-amber-fund-limited/register-investor>

Investors who already follow CRYSTAL AMBER FUND LIMITED on the Investor Meet Company platform will automatically be invited.

No new material information will be disclosed during the event. The slides of the presentation will subsequently be made available on morpichmedical.com.

For further enquiries please contact:

Sodali & Co - Financial PR adviser to Morpich Medical Inc

Victoria Palmer-Moore / Russ Lynch / Sam Austrums

Tel: 020 7250 1446

morpichmedical@sodali.com

Crystal Amber Fund Limited

Chris Waldron (Chairman)

Tel: 01481 742 742

www.crystalamber.com

Allenby Capital Limited - Nominated Adviser

Jeremy Porter/ Dan Dearden-Williams

Tel: 020 3328 5656

Winterflood Investment Trusts - Broker

Joe Winkley/Neil Langford

Tel: 020 3100 0160

Crystal Amber Advisers (UK) LLP - Investment Adviser

Richard Bernstein

Tel: 020 7478 9080

ABOUT MORPICH MEDICAL

[Morpich Medical](http://MorpichMedical) is the developer of RESET®, the first incision-free, endoscopically delivered therapy designed to treat obesity and related metabolic disorders such as type 2 diabetes.

RESET is a duodenal-jejunal bypass liner (DJBL) that is implanted and removed endoscopically, remaining in place for up to nine months. By creating a temporary barrier in the upper intestine, it has been shown to support significant weight loss and improved blood sugar control by enhancing natural gut hormone responses, in a way similar to GLP-1 therapies. Unlike gastric bypass surgery, RESET is minimally invasive and fully reversible.

RESET addresses a major global health need, with an estimated 93 million adults in Europe alone living with obesity and type 2 diabetes. It has been endorsed in the latest clinical guidelines for obesity treatment by both the European Society for Gastrointestinal Endoscopy (ESGE) and the American Society for Gastrointestinal Endoscopy (ASGE) - a strong validation from the medical community.

Founded in 2003, Morpich Medical is headquartered in Boston, Massachusetts. For more information, please visit morpichmedical.com or follow us on [X \(formerly Twitter\)](#) and / or [LinkedIn](#).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAPKOBKKBDKBKK